BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 16291042)

  • 1. PDE-5 inhibitors: current status and future trends.
    Masson P; Lambert SM; Brown M; Shabsigh R
    Urol Clin North Am; 2005 Nov; 32(4):511-25, viii. PubMed ID: 16291042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus.
    Vickers MA; Satyanarayana R
    Int J Impot Res; 2002 Dec; 14(6):466-71. PubMed ID: 12494279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction.
    Shabsigh R; Seftel AD; Rosen RC; Porst H; Ahuja S; Deeley MC; Garcia CS; Giuliano F
    Urology; 2006 Oct; 68(4):689-96. PubMed ID: 17070333
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral drug treatment of erectile dysfunction.
    Int J Impot Res; 2003 Dec; 15 Suppl 7():S27-9. PubMed ID: 14695970
    [No Abstract]   [Full Text] [Related]  

  • 5. [New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].
    MMW Fortschr Med; 2003 Jun; 145(26):59. PubMed ID: 12916343
    [No Abstract]   [Full Text] [Related]  

  • 6. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
    Katsarov M
    Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
    [No Abstract]   [Full Text] [Related]  

  • 8. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
    Chen Q; Wang N; Yao F; Lu X
    Zhonghua Nan Ke Xue; 2004 Apr; 10(4):302-4. PubMed ID: 15148932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.
    Ravipati G; McClung JA; Aronow WS; Peterson SJ; Frishman WH
    Cardiol Rev; 2007; 15(2):76-86. PubMed ID: 17303994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature.
    Gresser U; Gleiter CH
    Eur J Med Res; 2002 Oct; 7(10):435-46. PubMed ID: 12435622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Erectile dysfunction (ED) and diabetes mellitus].
    Takahashi Y
    Nihon Rinsho; 2005 Jun; 63 Suppl 6():553-7. PubMed ID: 15999768
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Deho' F; Zanni G; Barbieri L; Rigatti P; Montorsi F
    World J Urol; 2005 Dec; 23(6):374-84. PubMed ID: 16273417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
    Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Firoozi F; Longhurst PA; White MD
    BJU Int; 2005 Jul; 96(1):164-8. PubMed ID: 15963142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing all phosphodiesterase 5 inhibitors to a patient with erectile dysfunction--a realistic and feasible option in everyday clinical practice--outcomes of a simple treatment regime.
    Ströberg P; Hedelin H; Ljunggren C
    Eur Urol; 2006 May; 49(5):900-7; discussion 907. PubMed ID: 16564126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 5 inhibitors: current status and potential applications.
    Rotella DP
    Nat Rev Drug Discov; 2002 Sep; 1(9):674-82. PubMed ID: 12209148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [7 years PDE-5 inhibitor for therapy of erection disorders].
    Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
    [No Abstract]   [Full Text] [Related]  

  • 18. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
    Ghofrani HA; Grimminger F
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
    Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
    Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Visual loss with erectile dysfunction medications.
    Wooltorton E
    CMAJ; 2006 Aug; 175(4):355. PubMed ID: 16870715
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.